Q1 FY27 results: Revenue up 20.7% YoY to Rs 644 Cr; PAT at Rs 179 Cr
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Smallcap 250 and 5.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Caplin Point Labs posted strong Q1 FY27 results. Consolidated revenue grew 20.7% YoY to Rs 644 Cr, with revenue from operations up 19.6% at Rs 610 Cr. EBITDA rose 23% to Rs 247 Cr with margin expanding to 38.4%. PAT grew 18.8% YoY to Rs 179 Cr. EPS at Rs 23.27 vs Rs 20.10. Board recommended final dividend of Rs 4 per share (200%), taking total FY26 dividend to Rs 8 per share (400%). MD Dr Sridhar Ganesan reappointed for 2 years.
Strong broad-based growth with margin expansion and healthy dividend. Positive for shareholders; stock may see upward movement.